Neutralizing antibodies for SARS-CoV-2 infection

Abstract

The COVID-19 pandemic has boosted significant research in developing monoclonal antibodies (mAbs) to treat and pre-vent SARS-CoV-2 infection. Clinical trials have shown that mAbs are safe and effective in preventing hospitalization and death in patients with mild to moderate COVID-19 risk factors for progression. mAbs have also been effective for treating severe disease in seronegative patients and preventing COV-ID-19. So far, studies have been carried out in a largely unvac-cinated population at a time when the omicron variant was not described. Future research should address these limitations and provide information on specific population groups, includ-ing immunosuppressed and previously infected individuals.